Varian Halcyon Treatment System Receives China NMPA Approval

To view this release online and get more information about Varian visit: www.varian.com/newsroom PALO ALTO, Calif., Nov. 28, 2018 /PRNewswire/ -- Varian (NYSE: VAR) today announced its Halcyon™ system has been approved by the China National Medical Product Administration (NMPA), which allows the company to market this new cancer treatment system in China.  This approval further expands the global availability of Halcyon and access to high-quality, cost-effective cancer...This story is related to the following:Radiotherapy Systems
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news